Encephalopathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Encephalopathy – Pipeline Review, H2 2017’, provides an overview of the Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Encephalopathy

The report reviews pipeline therapeutics for Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Encephalopathy therapeutics and enlists all their major and minor projects

The report assesses Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Encephalopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Encephalopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Encephalopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corp

Chiesi Farmaceutici SpA

GW Pharmaceuticals Plc

JS Genetics Inc

Knopp Biosciences LLC

Marinus Pharmaceuticals Inc

Mithra Pharmaceuticals SA

ProThera Biologics Inc

SciFluor Life Sciences LLC

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Encephalopathy - Overview 6

Encephalopathy - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Encephalopathy - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Encephalopathy - Companies Involved in Therapeutics Development 20

Celgene Corp 20

Chiesi Farmaceutici SpA 20

GW Pharmaceuticals Plc 21

JS Genetics Inc 21

Knopp Biosciences LLC 21

Marinus Pharmaceuticals Inc 22

Mithra Pharmaceuticals SA 22

ProThera Biologics Inc 23

SciFluor Life Sciences LLC 23

Takeda Pharmaceutical Co Ltd 23

Encephalopathy - Drug Profiles 25

Alda-1 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

diazoxide - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Estetrol - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

ganaxolone - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GWP-42003 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

melatonin - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SF-0034 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Activate Kv7.2 for Encephalopathy, Epilepsy, Neuropathic Pain and Tinnitus - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

TAK-935 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

TRP-601 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Encephalopathy - Dormant Projects 53

Encephalopathy - Product Development Milestones 54

Featured News & Press Releases 54

Aug 21, 2017: Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies 54

Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 54

May 12, 2017: Ovid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference 55

Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 55

Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for Encephalopathy, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Encephalopathy – Pipeline by Celgene Corp, H2 2017 20

Encephalopathy – Pipeline by Chiesi Farmaceutici SpA, H2 2017 20

Encephalopathy – Pipeline by GW Pharmaceuticals Plc, H2 2017 21

Encephalopathy – Pipeline by JS Genetics Inc, H2 2017 21

Encephalopathy – Pipeline by Knopp Biosciences LLC, H2 2017 22

Encephalopathy – Pipeline by Marinus Pharmaceuticals Inc, H2 2017 22

Encephalopathy – Pipeline by Mithra Pharmaceuticals SA, H2 2017 22

Encephalopathy – Pipeline by ProThera Biologics Inc, H2 2017 23

Encephalopathy – Pipeline by SciFluor Life Sciences LLC, H2 2017 23

Encephalopathy – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 24

Encephalopathy – Dormant Projects, H2 2017 53

List of Figures

List of Figures

Number of Products under Development for Encephalopathy, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Top 10 Targets, H2 2017 12

Number of Products by Stage and Top 10 Targets, H2 2017 12

Number of Products by Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports